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Purpose: Selumetinib (AZD6244, ARRY-142886)
is an oral, potent, and selective allosteric mitogen-
activated protein kinase 1/2 inhibitor with a short t1/2.
The purpose of this study was to characterize the
effect of selumetinib on cardiac repolarization and a
potential exposure–QT effect relationship.
Methods: A double-blind (selumetinib), randomized,
3-period crossover study was conducted to assess the
effects of a single oral dose of selumetinib (75 mg) on the
QTc interval compared with placebo, using moxiﬂox-
acin as an open-label positive control, in healthy male
subjects aged 18 to 45 years. QT intervals were
evaluated by using the Fridericia formula (QTcF) and
the Bazett formula. Further analysis was conducted by
using nonlinear mixed effects modeling to characterize
any relationship between selumetinib exposure and QTc
and was used to predict the effect if selumetinib 150 mg
was administered. All adverse events were characterized
and recorded.
Findings: A total of 54 healthy male subjects were
enrolled, and 48 completed all treatments. Mean age
was 27 years; four subjects were of Hispanic or Latino
ethnicity, and 53.7% were White and 46.3% were
Black. The BMI of subjects ranged from 19.4 to 29.6
kg/m2. After a single oral dose of selumetinib 75 mg,
the highest upper bound of the 2-sided 90% CI for
placebo-corrected, baseline-adjusted QTcF (ΔΔQTcF)*Current afﬁliation: Covance, Early Clinical Biometrics, Leeds, UK.
†Current afﬁliation: Sandoz Pharmaceuticals, Holzkirchen,
Germany.
] 2016over the 24-hour postdose measurement interval was
2.5 milliseconds, which was well below the 10-
millisecond upper bound for concluding no effect.
The relationship between ΔΔQTcF and selumetinib
concentrations was adequately described by using a
nonlinear mixed effect model. The mean estimated
ΔΔQTcF interval prolongation based on the geo-
metric mean Cmax of 75 mg selumetinib was 2.38
milliseconds (90% CI, 1.25 to 3.52), which was in
good agreement with the statistical analysis results.
The model also predicted mean ΔΔQTcF interval
prolongations of 4.70 milliseconds (90% CI, 2.46 to
6.95) after a single supratherapeutic dose of selume-
tinib 150 mg, indicating the upper bound of 2-sided
90% CIs for ΔΔQTcF are predicted to be o10 milli-
seconds. Selumetinib, administered as a single 75 mg
oral dose, was generally safe and well tolerated.
Implications: Selumetinib 75 mg did not cause any
QT/QTc interval prolongation in these healthy
subjects, and selumetinib is not expected to have a
clinically relevant effect on cardiac repolarization
in patients at the anticipated therapeutic dose
of 75 mg. The model also demonstrated the low
potential for any QTc effects of selumetinib at
doses higher than the standard therapeutic dose.0149-2918/$ - see front matter
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Selumetinib (AZD6244, ARRY-142886) is an oral,
potent, and selective allosteric inhibitor of mitogen-
activated protein kinase (MEK)1/2.1 MEK is a critical
enzyme in the RAS/RAF/MEK/ERK pathway that
regulates key cellular activities, including proliferation,
survival, and cell cycle regulation. Selumetinib has
shown the ability to block cell proliferation in vitro,
regardless of sensitivity to conventional chemotherapy.2
It also effectively inhibited ERK phosphorylation and
suppressed proliferation in vivo in human melanoma–
bearing nude mice.3 In addition, selumetinib inhibited
acquisition of the breast cancer stem cell phenotype and
prevented lung metastasis of triple-negative breast
cancer in a xenograft model.4 Selumetinib is under
clinical development in a variety of indications, in-
cluding differentiated thyroid cancer (NCT01843062)
and neuroﬁbromatosis type 1 (NCT01362803).5,6
The pharmacokinetic (PK) proﬁle of selumetinib
has been studied in patients with various tumors.7,8 It
has a short t1/2 (mean, 5.33 hours), and its PK proﬁle
is approximately dose proportional from 25 mg up to
150 mg in patients with advanced cancer.8,9 The
N-desmethyl metabolite circulates at o10% of selu-
metinib in plasma.8 In cloned human ether-a-go-
go–related gene channels expressed in mammalian
cells, selumetinib produced no signiﬁcant effects at
up to the maximum test concentration (Investigator's
Brochure, Project Code D1532000000, 30 March
2015, AstraZeneca, UK), which is 700- to 1000-
fold greater than the half maximal inhibitory concen-
tration for inhibition of the activity of isolated MEK
in enzyme assays. In addition, N-desmethyl selumeti-
nib produced no signiﬁcant effects on the human
ether-a-go-go–related gene current at up to the max-
imum test concentration, 10-fold higher than that
was tested for selumetinib (Investigator's Brochure,
Project Code D1532000000, 30 March 2015, Astra-
Zeneca, UK). However, it is important to understand
—and it is a regulatory expectation to characterize—
any risk that new medicines prolong cardiac repola-
rization to identify any potential clinical consequences2such as torsade de pointes. Many drugs in a range of
indications do prolong the QTc interval, and some
have been found to have clinical consequences.10 This
outcome is particularly important in the oncology
setting in which a number of existing drugs have been
shown to prolong the QTc interval.11
The design of QT studies has been optimized in
recent times and usually contains a positive control
agent (eg, moxiﬂoxacin) and time-matched QTc read-
ings after dosing with placebo.12 In addition, the end
points and sizing of the studies have become
standardized. The primary objective of the present
study was to assess the effect of a single dose of
selumetinib (75 mg) on the change in time-matched
QT intervals evaluated by using the Fridericia formula
(QTcF) compared with placebo. In addition, the
safety, tolerability, and PK parameters of selumetinib
and its N-desmethyl metabolite were examined. In
support of the primary statistical analysis, an expo-
sure–response analysis between selumetinib concen-
trations and the placebo-corrected, baseline-adjusted
mean QTcF (ΔΔQTcF) was conducted.PATIENTS AND METHODS
Study Design
The study was conducted between March 2014
(ﬁrst subject enrolled) and August 2014 (last subject’s
last visit), and the clinical study protocol was ap-
proved by the MidLands Institutional Review Board
(Overland Park, Kansas). The study was performed
in accordance with the ethical principles that have
their origin in the Declaration of Helsinki and are
consistent with the International Conference on Har-
monisation/Good Clinical Practice and applicable regu-
latory requirements, as well as the AstraZeneca policy
on bioethics. Written informed consent was obtained
from all healthy subjects before initiation of the study.
This was a double-blind (selumetinib), placebo-
controlled, open-label (moxiﬂoxacin), positive-con-
trolled, randomized, 3-period crossover study to
assess the effects of a single oral dose of selumetinib
(75 mg) on QTc interval compared with placebo;
moxiﬂoxacin 400 mg was used as a positive control.
Moxiﬂoxacin was administered in an open-label
fashion due to its clear clinical signal of QT prolon-
gation and consistent PK proﬁle,13 and because at a
400 mg dose, it has no clinically signiﬁcant risk to
exposed healthy volunteers.14Volume ] Number ]
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75 mg BID of selumetinib as the maximum tolerated
dose, based on 2 dose-limiting toxicities in the 100 mg
BID dose cohort of grade 3 dermatitis acneiform and
grade 3 pleural effusion.8 The dose of selumetinib
75 mg was considered to be within the therapeutic
dose range and was the maximum dose permitted in
healthy volunteers. A BID dose of selumetinib 75 mg
has been investigated in other efﬁcacy studies, and
minimal accumulation of selumetinib was observed
after BID dosing for 8 days.9 Because a single dose of
selumetinib 75 mg was considered the highest acc-
eptable dose to be administered in healthy volunteers,
this study did not include a supratherapeutic
dose. Phase III trials of selumetinib used a dose of
75 mg BID.6,15,16
Study subjects were healthy, nonsmoking men aged
18 to 45 years with a body mass index between 18
and 30 kg/m2 and weight between 50 and 100 kg.
Subjects were to use barrier methods of contraception,
unless their partners were postmenopausal, surgically
sterile, or were using accepted contraceptive methods.
Key exclusion criteria were as follows: clinically
signiﬁcant disease or disorder; clinically important
abnormalities in the rhythm, conduction, or morphol-
ogy on a resting ECG recording; history of additional
risk factors for torsade de pointes; abnormal vital
signs; use of any prescribed medicine and over-the-
counter drugs within 2 weeks of administration of the
investigational product; and excessive intake of
caffeine-containing drinks or food.
Subjects were screened within 28 days before
randomization. During each 3-day treatment period,
each subject received the following on 1 occasion:
selumetinib (blinded), placebo (blinded; capsules
matched those of selumetinib), and moxiﬂoxacin
(open-label). The order in which the drugs were
administered was determined by randomization. The
randomization scheme was produced by Quintiles
(Overland Park, Kansas) by using the AstraZeneca
Global Randomization system (GRand), applying a
3-period, 3-treatment, Williams Latin square design.
Randomization codes were assigned strictly sequen-
tially as subjects became eligible for randomization.
Each administration was separated by a washout
period of at least 3 days. Subjects underwent an
8-hour fast before dosing, and no food intake was
allowed until 4 hours after dosing. The subjects were
allowed no ﬂuid intake from 1 hour before the] 2016investigational product administration until 1 hour
after, except for the water needed to swallow the
investigational product.
Pharmacodynamic Measurements
Twelve-lead continuous digital ECG (dECG) re-
cordings were obtained by using Schiller Cardiovit
CS-200 ECG recorders (Schiller AG, Baar, Switzer-
land). The analyses of all dECGs were performed at
the AstraZeneca ECG Centre (AstraZeneca ECG Core
Lab, Gothenburg, Sweden) in fully blinded mode
(ie, blinded to sequence, treatment, time and subject
identiﬁer). The waveform analysis was performed by
using the EClysis System (ECG Analysis, AstraZeneca
proprietary tool, Gothenburg, Sweden), a software
tool for automated dECG waveform reading, annota-
tion, and interval calculation that also allows manual
adjudication (ie, a semi-automated analysis).12,17,18
No clinically meaningful effects induced by selume-
tinib or N-desmethyl selumetinib on heart rate (HR)
have been observed in previous studies. Continuous
12-lead dECG recordings were captured for 20 mi-
nutes predose at baseline and for 5 minutes at time
points 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours
postdose. All dECG recordings were obtained after at
least 10 minutes of supine rest at all time points and
just before supine vital signs and blood sample
collection for PK assessments. For QTcF measure-
ments, the precordial lead V2 was used as the primary
lead; precordial lead V5 was used as the backup lead
for all time points when lead V2 was found to be
unsuitable for analysis and evaluation. The QT inter-
val was measured (in milliseconds) from the onset of
the QRS complex to the end of the T wave, which was
determined by use of a tangent on the T-wave down
slope and the intercept with the iso-electric line. Using
EClysis software, the tangent was derived between the
20% and 80% repolarization points on the T wave
calculated from the top of the T wave to the iso-
electric line.17
The dECG-collected or -derived variables were as
follows: the QT interval (measured from the onset of
the QRS-complex to the end of the T wave); the QTcF
in milliseconds; HR in beats per minute; the RR
interval (the time between corresponding points on
2 consecutive R waves in seconds); the PR interval
(measured from the onset of the P wave to the onset of
the QRS complex in milliseconds); the QRS duration
(the interval measured from the onset of the QRS3
Clinical Therapeuticscomplex to the J point in milliseconds); and the QT
interval corrected for HR by using the Bazett formula
(QTcB) in milliseconds. Ten-second dECG replicates
were extracted every 30 seconds from the predeﬁned
5- or 20-minute continuous recordings. The extracted
data were averaged to arrive at a mean value for each
time point. The QT interval was corrected for RR
interval to obtain QTc variables. The general formula
for QTc was QT / RRb, with QT intervals expressed in
milliseconds and the RR interval in seconds. The
formula for QTcF was b ¼ 1/3,12 and for QTcB,
b ¼ 1/2.12
PK Assessments
Plasma PK samples were collected for selumetinib,
N-desmethyl selumetinib, and moxiﬂoxacin at predose
and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48
hours postdose to capture the PK proﬁle of these
drugs. Covance Laboratories, Inc (Madison, Wiscon-
sin), performed the analysis of plasma samples for
selumetinib, N-desmethyl selumetinib, and moxiﬂox-
acin concentrations as part of the AstraZeneca–
Covance Clinical Bioanalysis Alliance. Sensitive
LC-MS/MS assays were developed and validated that
demonstrated acceptable precision, accuracy, and
selectivity for selumetinib and its metabolites in the
appropriate matrices.19 They were validated based on
guidance from the US Food and Drug Administration
and the European Medicines Agency20–22 and on
standard laboratory operating procedures. To demon-
strate acceptable in-study performance, incurred sam-
ple reproducibility experiments were also performed.
Selumetinib and N-desmethyl selumetinib were ex-
tracted from human plasma treated with K2EDTA
anticoagulant by protein precipitation and analyzed
by using liquid chromatography with a Sciex API (AB
Sciex LLC, MA, USA) 5000 or 5500 triple/quad
tandem mass spectrometer. The method used stable
label carbon-13 internal standards and was validated
over the range of 2 to 2000 ng/mL for selumetinib and
2 to 500 ng/mL for N-desmethyl selumetinib. The
ability to dilute overrange samples was also conﬁrmed.
Moxiﬂoxacin was extracted from human plasma
treated with K2EDTA anticoagulant by protein pre-
cipitation and analyzed by using liquid chromatogra-
phy with a Sciex API 4000 tandem mass spectrometer.
The method uses a stable label deuterated internal
standard and was validated over the range of 25 to
5000 ng/mL for moxiﬂoxacin. AUC0–t, Cmax, and4Tmax were calculated for selumetinib, N-desmethyl
selumetinib, and moxiﬂoxacin.
Study End Points
The primary end point in this study was the
effect of a single dose of selumetinib (75 mg) on the
change in time-matched QTcF interval compared with
placebo. Secondary end points included: the effect of
selumetinib on QRS, QT, HR, RR, PR, and QTcB;
mean changes in time-matched QTcF interval after
moxiﬂoxacin administration compared with placebo;
PK examination of selumetinib, N-desmethyl selume-
tinib, and moxiﬂoxacin; the relationship between
plasma concentration and cardiac ventricular repola-
rization effect on the heart after a single oral dose of
selumetinib or moxiﬂoxacin by assessments of plasma
concentrations of selumetinib, moxiﬂoxacin, and the
QT/QTcF interval on dECGs; and assessment of the
safety and tolerability of selumetinib.
Statistical Analysis
Assuming a 3-millisecond effect of selumetinib on
QTcF, an 8.5-millisecond residual variability, and 10
postdose ECG assessments, 47 evaluable subjects were
needed to provide490% power to conclude no effect
on QTcF at or above the 10-millisecond threshold; to
allow for discontinuations, 54 healthy subjects were
randomized to study. The safety analysis set included
all subjects who received at least 1 dose of treatment
(selumetinib, placebo, or moxiﬂoxacin). The PK anal-
ysis set included all subjects who received at least 1
dose of selumetinib or moxiﬂoxacin and had at least 1
postdose PK measurement with no important events
or protocol deviations thought to signiﬁcantly affect
the PK parameters of the drug.
The pharmacodynamic (PD) analysis set included
all subjects who received at least 1 dose of treatment
(selumetinib, placebo, or moxiﬂoxacin) and had at
least 1 postdose QT measurement with no important
events or protocol deviations thought to signiﬁcantly
affect the QT. The primary analysis of change from
baseline for QTcF was conducted by using a repeated
measures linear mixed model with ﬁxed effects for
treatment, period, time, period-by-time interaction,
treatment-by-time interaction, and the baseline value
(predose from each period) as a covariate. Subjects
were treated as a random effect, and time was treated
as a repeated effect, within a subject period, using a
ﬁrst-order autoregressive covariance structure. At eachVolume ] Number ]
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means with corresponding 2-sided 90% CIs for
selumetinib compared with placebo were calculated;
the upper CI bounds needed to be o10 milliseconds
to conclude no effect on the QTcF interval.
In addition, a sensitivity analysis was performed in
which the treatment comparison (selumetinib vs placebo)
was performed at each time point, using an ANCOVA
model with subject as a random effect, period and
treatment as ﬁxed effects, and baseline QTcF (predose
from each period) as a covariate. The same statistical
model as described for the primary analysis of QTcF was
used to assess the effect of treatment for change from
baseline of QTcB, QT, HR, RR, QRS, and PR.
To assess the assay sensitivity of the study, the
treatment effect of moxiﬂoxacin (from the aforemen-
tioned model) was evaluated by estimating the mean
difference from placebo for the mean of QTcF during
the 1- to 4-hour interval postdose with a correspond-
ing 2-sided 90% CI. The lower bound of this 2-sided
interval was required to be 45 milliseconds to
establish assay sensitivity.
Concentration-QTc Effect Modeling
A population concentration-effect model describing
the relationship between selumetinib concentrations
and the baseline-subtracted, placebo-corrected QTc
(ΔΔQTcF) was established by using a nonlinear mixed
effects modeling approach with NONMEM version
7.3 (ICON, Hanover, Maryland) and the ﬁrst-order
conditional estimation method with interaction.23
Linear or Emax-type of nonlinear relationships of
ΔΔQTcF versus selumetinib concentrations was
examined. Models were progressed by using the
Akaike information criterion24 as ΔOFV þ 2Δdf,
where ΔOFV and Δdf are the difference in the
objective function value (OFV) of NONMEM and
the difference in number of model parameters between
the competitive model and the reference model (degree
of freedom).
The predictive performance of the ﬁnal ΔΔQTcF–
concentration model was assessed with a visual
predictive check. Simulation of 1000 new datasets
was conducted by using the ﬁnal model with the
estimated ﬁxed effects and random effects model
parameters. The ΔΔQTcF-concentration proﬁles were
plotted for the 50th percentile and the 5th and 95th
percentiles (presenting the 90% prediction interval) of
the simulated data and overlaid with observed data.] 2016Nonparametric bootstrapping (1000 replicates) was
also conducted, and empirical 95% CIs were con-
structed by obtaining the 2.5th and 97.5th percentiles
of the resulting parameter distributions for those
bootstrap runs with successful convergence. The ﬁnal
model parameter estimates were compared with the
bootstrap median parameter estimates to evaluate the
ﬁnal model performance.
The potential ΔΔQTcF prolongation for antici-
pated selumetinib therapeutic dose (75 mg) was
evaluated at geometric mean Cmax of selumetinib with
the upper bound of the 2-sided 90% CI of the
population mean estimate of the slope.25 In addition,
the model was also applied to predict the potential
ΔΔQTcF prolongation if a higher dose is administered.
The geometric mean Cmax of selumetinib observed in
patients with advanced solid tumors after a single dose
of 150 mg selumetinib was used.9
Tolerability Assessment
Vital sign measurements, physical examinations,
and safety laboratory analyses involving routine hem-
atology, serum chemistry, and urinalysis were ob-
tained and reviewed by the investigator during the
study and at a follow-up examination. All adverse
events (AEs) were evaluated by the investigator and
characterized with respect to intensity, duration,
relationship to study drug, and outcome.RESULTS
Subject Demographic Characteristics
A total of 54 healthy subjects were randomized to
treatment. Forty-eight subjects completed the treat-
ments, and 47 completed the study: 3 subjects were
lost to follow-up; 2 were withdrawn due to protocol
deviations; and 2 withdrew consent. Subject disposition
is described in Figure 1. All subjects were male, with a
mean age of 27 years (range, 18–45 years). Four
subjects were of Hispanic or Latino ethnicity, and
there was approximately equal distribution between
white (53.7%) and black (46.3%) subjects. The body
mass index of subjects ranged from 19.4 to 29.6 kg/m2.
PD Profile
A total of 50 subjects treated with selumetinib or
moxiﬂoxacin and 49 subjects treated with placebo
were available for QTc interval analysis. The
ΔΔQTcF for selumetinib 75 mg was o5 milliseconds5
QTc interval analysis
• Subjects treated with selumetinib or 
moxifloxacin: (n = 50)
• Subjects receiving placebo (n = 49)
Analysis
PK-PD analysis
• Analyzed (n = 47)*
• Allocated to intervention (n = 54)
• Received allocated intervention (n = 54)
Safety analysis
• Subjects treated with selumetinib or 
moxifloxacin: (n = 51)
• Subjects receiving placebo (n = 50)
• Overall: (n = 54)
• Lost to follow-up (n = 3)
• Protocol deviation (n = 2)
• Withdrawal by subject (n = 2)
Randomized (N = 54)
Follow-up
Enrollment
Allocation
Figure 1. Subject disposition. *Forty-eight subjects completed the study; 1 subject was excluded from
statistical and pharmacokinetic (PK)/pharmacodynamic (PD) analysis due to protocol deviation.
Clinical Therapeuticsat each time point, and all upper limits of the 2-sided
90% CI were well below 10 milliseconds (Figure 2).
The highest upper bound of the 2-sided 90% CIs for
ΔΔQTcF over the 24-hour postdose measurement
interval was 2.5 milliseconds at 1.5 hours after dosing.
Similar results were obtained from the sensitivity
analysis, with the highest upper bound of the
2-sided 90% CIs for ΔΔQTcF at 2.3 milliseconds.
Similar ﬁndings were observed by using QTcB; the
highest upper bound of the 2-sided 90% CIs for
ΔΔQTcB over the 24-hour postdose measurement
interval was 3.2 milliseconds.
After a single oral dose of moxiﬂoxacin 400 mg,
the largest ΔΔQTcF increase of 11.9 milliseconds
(95% CI, 10.3 to 13.6) was observed 3 hours after
dosing. Assay sensitivity was demonstrated by com-
paring moxiﬂoxacin and placebo QTcF averaged
over the 1- to 4-hour range postdose, using the
mixed effects ANCOVA model. The lower bound
of the 2-sided 90% CI for mean ΔΔQTcF over the
1- to 4-hour time interval postdose was 45 milli-
seconds (ie, 9.4 milliseconds), thereby establishing
assay sensitivity.6Changes from baseline to the observed maximum
in QTcF or QTcB did not exceed 30 milliseconds at
any time point over the 24-hour period after dosing
with selumetinib 75 mg or placebo. There were no
subjects with absolute QTcF or QTcB values 4450
milliseconds.
There were no HR events for selumetinib or
placebo that met the predeﬁned criterion of 4100
beats/min. Three subjects receiving selumetinib treat-
ment and 1 subject taking placebo had a PR interval
4200 milliseconds. All of these subjects had high PR
intervals at baseline (range, 194–199 milliseconds),
and the change from baseline was actually small
(range, 3–7 milliseconds), bringing the PR intervals
to just over 200 milliseconds (range, 201–207 milli-
seconds). Four subjects receiving selumetinib treat-
ment and 5 subjects taking placebo had a QRS
interval 4110 milliseconds. All of these subjects
who had a QRS interval 4110 milliseconds with treat-
ment had a QRS interval4110 milliseconds at baseline,
as well as at predose for some subjects. Therefore, none
of these PR or QRS events was considered clinically
signiﬁcant by the principal investigator.Volume ] Number ]
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Figure 2. Least-squares means and 90% CIs for
placebo-subtracted change-from-base-
line QT interval corrected according to
Fridericia’s formula quantifiable con-
centration (QTcF) for selumetinib
75 mg single-dose treatment or moxi-
floxacin 400 mg single-dose treatment.
ΔΔQTcF ¼ placebo-corrected change-
from-baseline in QTcF.
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The PK proﬁles showed that selumetinib was
rapidly absorbed after oral administration; median
Tmax for selumetinib and N-desmethyl selumetinib
occurred at 1 hour postdose (Table I). The
geometric mean metabolite-to-parent ratios for
AUC0-1 and Cmax were 0.0802 and 0.0733, respec-
tively. The arithmetic mean apparent clearance was
19.0 L/h, which is close to the reported average valueTable I. Summary statistics of selumetinib, N-desmet
parameters. Values are given as geometric mea
(SD) for t1/2, CL/F, and Vss/F.
Parameter
Selumetinib
(n ¼ 50)
AUC0–t, ng  h/mL 3980 (24.6)*
Cmax, ng/mL 1240 (33.1)
†
Tmax, median (minimum–maximum), h 1.02 (0.5–2.5
t1/2, h 9.18 (2.64)
CL/F, L/h 19.0 (4.66)
Vss/F, L 145 (46.5)
NA ¼ not applicable; Vss/F ¼ apparent volume of distribution
*n ¼ 49.
†One ng/mL equals 2.18 nM of selumetinib.
] 2016of 16.0 L/h with a range of 7.77 to 33.3 L/h.8 The
arithmetic mean Vss/F was 145 L, which is also similar
to the reported average value of 106.7 L with range of
52.3 to 219 L.8 The geometric mean AUC0–t and
Cmax for moxiﬂoxacin was 22,700 ng h/mL and
1690 ng/mL, respectively, after administration of
moxiﬂoxacin 400 mg. The PK parameters of moxi-
ﬂoxacin observed in this study were similar to those in
the published literature.26
PK/PD Analysis
The ΔΔQTcF dataset included 47 subjects with
468 observations with the range of selumetinib concen-
tration between 2.41 and 2325.14 ng/mL. The relation-
ship between selumetinib concentration and ΔΔQTcF
was tested by using linear function and nonlinear
Emax-type function. Random effects (IIV) were tested
on the intercept, slope, maximum ΔΔQTcF interval
prolongation (Emax), or half maximal effective concen-
tration (EC50). The linear model with IIV on intercept
was the best model to describe the selumetinib concen-
tration and ΔΔQTcF relationship. The ﬁnal model
parameter estimates and bootstrap results are presented
in Table II.
The parameter of interest in the model was the
coefﬁcient for the concentration effect (slope of a linear
model), which represents the effect of the drug on
ΔΔQTcF. The 95% CI for the slope parameter did not
include 0, indicating that the data support a prolonga-
tion of the QTcF interval. All model parameters werehyl-selumetinib, and moxifloxacin pharmacokinetic
n (%CV) for Cmax and AUC and as arithmetic mean
N-desmethyl-selumetinib
(n ¼ 50)
Moxiﬂoxacin
(n ¼ 50)
285 (29.3) 22,700 (20.3)
90.4 (38.3) 1690 (29.5)
) 1.02 (0.5–3.0) 1.53 (0.5–4.0)
8.18 (2.77) 13.1 (2.08)
NA 16.5 (3.55)
NA 303 (53.3)
at equilibrium.
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Table II. Final model parameter estimates and bootstrap results.
Parameter Population Estimate RSE, %
Bootstrap
Median 95% CI
Fixed effects
θ1 – intercept –1.16 95 –1.12 –3.10 to 1.11
θ2 – slope (nM–1) 0.00088 29 0.000907 0.000426 to 0.001446
IIV (ω) intercept 7.3 36 7.0 4.67 to 9.57
Residual error additive 5.1 11 4.6 4.50 to 5.61
IIV ¼ interindividual variability; RSE ¼ relative standard error.
Clinical Therapeuticswell estimated with good precision (small relative SE),
except for the intercept parameter θ1. The intercept
parameter was expected to be 0 on average and could not
be well estimated because it represents a drug-unrelated
random effect due to baseline and placebo subtraction by
deﬁnition. The estimate of the intercept from the ﬁnal
model was –1.16, and the 95% CI estimated from the
bootstrap (–3.10 to 1.11) included 0, which agrees with
the interpretation of the intercept parameter.
The predictive performance of the ﬁnal population
PK/PD model was assessed by using a visual predictive
check. Overlay plots of the ΔΔQTcF versus observed
selumetinib concentration with the 95% prediction
interval of the simulated data indicated that data
simulated from the ﬁnal model were consistent with
the observed data (Figure 3).
In the selumetinib QT study, the geometric mean
Cmax of selumetinib at a single 75 mg dose was 1240
ng/mL. Therefore, the mean estimated ΔΔQTcF inter-
val prolongation was 2.38 milliseconds (90% CI, 1.25
to 3.52). The predicted mean and upper bound of
2-sided 90% CIs for ΔΔQTcF were o5 milliseconds
at this dose, which is in agreement with the statistical
analysis results. The model also predicted mean
estimated ΔΔQTcF interval prolongations of 4.70
milliseconds (90% CI, 2.46 to 6.95) by using the
observed geometric mean Cmax of 2447 ng/mL after a
single dose of 150 mg selumetinib in patients with
advanced solid tumors.9 The predicted upper bound
of 2-sided 90% CIs for ΔΔQTcF was o10 millisec-
onds at this dose, which is double the anticipated
Phase III dose. Of note, the Cmax observed in the
patient study using 150 mg selumetinib was approx-
imately twice that observed in the current 75 mg8selumetinib study and thus is supportive of dose-
exposure linearity at these doses.Tolerability
There were no deaths or AEs resulting in discontin-
uation of selumetinib, moxiﬂoxacin, or placebo for
any subject. There were no serious AEs in subjects
during selumetinib or moxiﬂoxacin treatment and 1
serious, noncausally related AE (hemorrhoids) during
placebo treatment. Overall, the percentage of subjects
who reported at least 1 AE was similar across all 3
study groups (selumetinib, 9.8%; moxiﬂoxacin, 9.8%;
and placebo, 10%). The number (%) of subjects who
had at least 1 AE according to System Organ Class is
listed in Table III. Headache was the most commonly
reported AE in all 3 study arms. All nonserious AEs
were of mild intensity and considered unrelated to the
investigational product by the principal investigator.
There were no clinically relevant abnormal laboratory
variables, physical examination, and/or vital signs
ﬁndings throughout the study.DISCUSSION
This randomized, placebo- and positive-controlled cross-
over QTc study assessed a single 75 mg dose of
selumetinib in healthy subjects. The results indicate that
selumetinib had no clinically signiﬁcant effect on the QT/
QTcF interval at this therapeutic dose. Speciﬁcally, the
highest upper bound of the 2-sided 90% CIs for the
placebo-corrected ΔΔQTcF value over the 24-hour
postdose measurement interval was 2.5 milliseconds,
which is well below the 10-millisecond protocol-deﬁned
upper bound 90% CI value for regulatory concern.Volume ] Number ]
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Figure 3. Visual predictive check of the final
pharmacokinetic (PK)/pharmacody-
namic (PD) model. The observed pla-
cebo-corrected change-from-baseline
in QT interval corrected according
to Fridericia’s formula quantifiable
concentration (ΔΔQTcF) versus
selumetinib concentrations from the
selumetinib QT study are plotted with
95% prediction intervals calculated
from the 1000 simulation replicates
overlaid. Values are presented as open
circles. Median observed concentra-
tions are presented as a red line with
95% CIs represented as dashed lines.
Median prediction is presented as the
red shaded area and 95% prediction
intervals are presented as the blue
shaded area.
D. Zhou et al.In addition, there were no absolute QTc interval
increases 430 milliseconds from baseline with selume-
tinib treatment. In contrast, the positive control, moxi-
ﬂoxacin, lengthened the QTc interval, with the largest
ΔΔQTcF increase of 11.9 milliseconds and a lower
bound of 45 milliseconds (9.4 milliseconds) for the 2-
sided 90% CI for mean ΔΔQTcF over the 1- to 4-hour
time interval postdose, thus demonstrating assay sensi-
tivity of the study. There were no additional clinically
signiﬁcant effects of either selumetinib or moxiﬂoxacin
on the PR or QRS intervals.] 2016The relationship between selumetinib concentration
and ΔΔQTcF was adequately described by using a
nonlinear mixed effect PK/PD model. The mean
estimated ΔΔQTcF interval prolongations based on
the geometric mean Cmax of 75 mg (2.38 milliseconds
[90% CI, 1.25 to 3.52]) was in agreement with the
primary statistical analysis result, providing further
evidence that selumetinib does not have an effect on
QTc. In addition, the PK/PD model also predicted
mean ΔΔQTcF interval prolongations of 4.70 milli-
seconds (90% CI, 2.46 to 6.95) after a single dose of
selumetinib 150 mg in patients. Overall, selumetinib
was well tolerated in this study, with no HR events
that met predeﬁned criterion.
Consistent with our study, clinical trials involving
other MEK inhibitors (eg, trametinib, binimetinib,
PD-0325901) do not report prolongation of QT
interval as a concern.27–29 For example, in a Phase I
study investigating trametinib in patients with solid
tumors or lymphoma, an exposure–response analy-
sis was conducted to examine the relationship be-
tween plasma concentrations of trametinib and QTc
interval.27 The predicted upper limit of the 90% CI
change in QTcP (QTc corrected for HR by using a
population factor) after a 2 mg dose of trametinib was
4.0 milliseconds (median, 2.2 milliseconds), indicating
no effect of trametinib on QT interval. In addition, in
a Phase Ib/II study of binimetinib in combination with
LEE011 (an oral CDK4/6 inhibitor) in patients with
advanced NRAS-mutant melanoma, no clinically sig-
niﬁcant QTcF prolongation was reported.28
The design of the present study followed estab-
lished guidelines for the clinical evaluation of QT/QTc
interval and included a positive control group, a
placebo control group, appropriate blinding, and
randomization in healthy subjects.12 It is generally
believed that a QT-prolonging effect can be demon-
strated in healthy subjects if a drug has such an effect
in patients.14 In addition, the PK proﬁle of a single
dose of selumetinib in this study was similar to that in
other healthy subjects and patient studies with
selumetinib.9,30 The PK proﬁle of selumetinib exhibited
minimal accumulation of selumetinib after chronic
multiple dosing at 75 mg BID due to the drug’s short
t1/2.
8 Previous studies have shown that the PK proﬁle of
selumetinib is broadly similar between patients and
healthy subjects, although larger variability was
observed in patient studies7,8 and, therefore, our ﬁnd-
ings should be applicable to patients.9
Table III. Subjects who had at least 1 adverse event (AE) by Preferred Term, arranged according to System
Organ Class.
System Organ Class/Preferred Term
No. (%) of Subjects
Selumetinib
75 mg
(n ¼ 51)
Moxiﬂoxacin
400 mg
(n ¼ 51)
Placebo
(n ¼ 50)
Overall
(n ¼ 54)
Subjects with any AE 5 (9.8) 5 (9.8) 5 (10.0) 13 (24.1)
Gastrointestinal disorders 0 3 (5.9) 1 (2.0) 4 (7.4)
Abdominal pain 0 1 (2.0) 0 1 (1.9)
Dyspepsia 0 1 (2.0) 0 1 (1.9)
Hemorrhoids 0 0 1 (2.0) 1 (1.9)
Rectal hemorrhage 0 1 (2.0) 0 1 (1.9)
Immune system disorders 0 0 1 (2.0) 1 (1.9)
Hypersensitivity 0 0 1 (2.0) 1 (1.9)
Musculoskeletal and connective tissue
disorders
0 1 (2.0) 2 (4.0) 3 (5.6)
Arthralgia 0 0 1 (2.0) 1 (1.9)
Musculoskeletal pain 0 0 1 (2.0) 1 (1.9)
Pain in extremity 0 1 (2.0) 0 1 (1.9)
Nervous system disorders 3 (5.9) 2 (3.9) 0 5 (9.3)
Headache 3 (5.9) 1 (2.0) 0 4 (7.4)
Disturbance in attention 0 1 (2.0) 0 1 (1.9)
Psychiatric disorders 1 (2.0) 0 0 1 (1.9)
Insomnia 1 (2.0) 0 0 1 (1.9)
Skin and subcutaneous tissue disorders 1 (2.0) 0 1 (2.0) 2 (3.7)
Blister 1 (2.0) 0 0 1 (1.9)
Skin irritation 0 0 1 (2.0) 1 (1.9)
A subject could have hadZ1 Preferred Terms reported under a given System Organ Class; AEs occurring during the washout
period between treatments were attributed to the last treatment received before washout.
Clinical TherapeuticsThe effect of a supratherapeutic dose of selumetinib
on cardiac ventricular repolarization could not be
explored in this study, as the maximum safety limit
set by AstraZeneca is 75 mg as a single dose; the
maximum tolerated dose in patients was also consid-
ered to be 75 mg.8 However, the PK/PD model in the
present analysis established that the upper bound of
the 2-sided 90% CI for ΔΔQTcF was o10 milli-
seconds for a 150 mg single dose, which is double that
of the Phase III dose, demonstrating the low potential
for any QTc effects of selumetinib at doses higher than
the standard therapeutic dose. Furthermore, because
minimal accumulation in Cmax has been observed
with repeat dosing,8 selumetinib at the proposed10therapeutic dose of 75 mg BID is unlikely to have a
clinically relevant effect on cardiac repolarization in
patients.
Finally, selumetinib and N-desmethyl selumetinib
are metabolized by cytochrome P450 (CYP) 1A2,
CYP2C19, and CYP3A4 enzymes, with CYP1A2
being primarily responsible for the formation of the
N-desmethyl metabolite in vitro in human liver micro-
somes (unpublished data, in vitro selumetinib metabo-
lism studies). Coadministration of selumetinib with the
potent CYP3A4 inhibitor itraconazole or the potent
CYP2C19 inhibitor ﬂuconazole increases selumetinib
exposure by 50%.31 Caution may therefore be
required when coadministering selumetinib with theseVolume ] Number ]
D. Zhou et al.types of inhibitors due to other AEs; however, the effect
of selumetinib on cardiac repolarization could still be
minimal as the established PK/PD model demonstrated
low potential for any QTc effects of selumetinib even at
a supratherapeutic 150 mg dose.CONCLUSIONS
A single 75 mg dose of selumetinib was not associated
with QT/QTc interval prolongation in these healthy
male subjects. The PK/PD model demonstrated the low
potential for any QTc effects of selumetinib at a 150 mg
single dose, which is twice the anticipated therapeutic
dose. Therefore, selumetinib at the proposed therapeutic
dose of 75 mg BID is unlikely to have a clinically
relevant effect on cardiac repolarization in patients.ACKNOWLEDGMENTS
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